Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2

Clinical Trial ID NCT00281658

Rank	Title	Journal	Year	PubWeight™‹?›
1	Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.	J Clin Oncol	2013	2.44
2	Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen.	Breast Cancer Res Treat	2012	0.89
3	Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone.	Breast Cancer Res	2014	0.84
4	The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents.	Bioorg Med Chem	2014	0.80
5	Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer.	Breast Cancer (Dove Med Press)	2012	0.79
6	Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies.	Ther Adv Med Oncol	2016	0.75